Viatris Expects First Interchangeable Biosimilar Designations For Insulins In July

Firm Expecting Landmark Nods For Both Glargine And Aspart

 
• By Dean Rudge
  
FDA building.
July is a key month for Viatris' FDA insulin application • Source: Shutterstock

More from Biosimilars

More from Products